Role of Dual-Staining p16/Ki-67 in the Management of Patients under 30 Years with ASC-US/L-SIL.
HPV
Ki-67
colposcopy
immunohistochemistry
immunostaining
p16
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
04 Feb 2022
04 Feb 2022
Historique:
received:
27
12
2021
revised:
25
01
2022
accepted:
02
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Patients diagnosed with low-grade squamous intraepithelial lesion ((L-SIL) or atypical squamous cells of undetermined significance (ASC-US) are subjected to additional investigations, such as colposcopy and biopsy, to rule out cervical intraepithelial neoplasia 2+ (CIN 2+). Especially in young patients, lesions tend to regress spontaneously, and many human papilloma virus (HPV) infections are transient. Dual-staining p16/Ki-67 has been proposed for the triage of patients with ASC-US or L-SIL, but no prospective study addressing only this subgroup of patients has been conducted so far. We performed a prospective study including all eligible patients referred for a loop electrosurgical excision procedure (LEEP) in the Department of Obstetrics and Gynecology of Timișoara University City Hospital. HPV genotyping and dual-staining for p16/Ki-67 were performed prior to LEEP, at 6 and 12 months after LEEP. A total of 60 patients were included in the study and completed the follow-up evaluation. We analyzed the sensitivity and specificity for biopsy-confirmed CIN2+ using the 95% confidence interval (CI) of high-risk human papilloma virus (HR-HPV), dual-staining p16/Ki-67, colposcopy, and combinations of the tests on all patients and separately for the ASC-US and L-SIL groups. Dual-staining p16/Ki-67 alone or in combination with HR-HPV and/or colposcopy showed a higher specificity that HR-HPV and/or colposcopy for the diagnosis of biopsy confirmed CIN2+ in patients under 30 years. Colposcopy + p16/Ki-67 and HR-HPV + colposcopy + p16/Ki-67 showed the highest specificity in our study.
Identifiants
pubmed: 35204494
pii: diagnostics12020403
doi: 10.3390/diagnostics12020403
pmc: PMC8870853
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Victor Babeș University of Medicine and Pharmacy Timișoara
ID : IMUNO-CERV
Références
Int J Cancer. 2017 Jan 15;140(2):423-430
pubmed: 27677098
PLoS One. 2015 Jul 31;10(7):e0134445
pubmed: 26230097
J Cell Mol Med. 2009 Apr;13(4):648-59
pubmed: 19166485
Int J Cancer. 2005 Sep 10;116(4):617-23
pubmed: 15818610
Am J Clin Pathol. 2000 Nov;114(5):735-40
pubmed: 11068547
Lancet Oncol. 2006 Jul;7(7):547-55
pubmed: 16814206
Oncol Lett. 2016 Feb;11(2):1447-1452
pubmed: 26893758
Cytopathology. 2017 Jun;28(3):192-202
pubmed: 28029192
Int J Cancer. 2009 Feb 1;124(3):516-20
pubmed: 18973271
Gynecol Oncol. 2015 Feb;136(2):189-97
pubmed: 25579108
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884
Int J Cancer. 2004 May 20;110(1):94-101
pubmed: 15054873
Clin Cancer Res. 2012 Aug 1;18(15):4154-62
pubmed: 22675168
Br J Cancer. 2005 Oct 17;93(8):862-7
pubmed: 16189520
N Engl J Med. 2007 Oct 18;357(16):1579-88
pubmed: 17942871
Diagn Cytopathol. 2020 Jul;48(7):635-644
pubmed: 32275355
Am J Clin Pathol. 2010 Mar;133(3):395-406
pubmed: 20154278
J Low Genit Tract Dis. 2014 Apr;18(2):142-50
pubmed: 24270192
J Low Genit Tract Dis. 2005 Apr;9(2):100-7
pubmed: 15870531
Cancers (Basel). 2021 Jul 01;13(13):
pubmed: 34282754
Mod Pathol. 2003 Jul;16(7):665-73
pubmed: 12861062
N Engl J Med. 2007 Oct 18;357(16):1589-97
pubmed: 17942872
Cancer. 2006 Mar 1;106(5):1054-64
pubmed: 16421920
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1185-9
pubmed: 21527581
Cytopathology. 2015 Feb;26(1):10-8
pubmed: 24261348
J Low Genit Tract Dis. 2020 Apr;24(2):102-131
pubmed: 32243307
Cancer Cytopathol. 2015 Apr;123(4):212-8
pubmed: 25534957
Clin Microbiol Infect. 2020 May;26(5):579-583
pubmed: 31539637
Cancer Cytopathol. 2015 Jun;123(6):373-81
pubmed: 25891096
J Natl Cancer Inst. 2008 Apr 2;100(7):492-501
pubmed: 18364502
J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23
pubmed: 19903804
Obstet Gynecol. 2013 Apr;121(4):829-846
pubmed: 23635684
Int J Cancer. 2015 May 15;136(10):2361-8
pubmed: 25345358
Diagn Cytopathol. 2010 Jun;38(6):407-12
pubmed: 19894254
Int J Cancer. 2006 Feb 15;118(4):791-6
pubmed: 16287075
Obstet Gynecol. 2015 Feb;125(2):308-310
pubmed: 25569012
Am J Clin Pathol. 1991 Oct;96(4):444-6
pubmed: 1716412
Int J Cancer. 2007 Jul 15;121(2):361-7
pubmed: 17354241
Obstet Gynecol. 1999 Aug;94(2):307-10
pubmed: 10432148
Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83
pubmed: 28881916
Int J Cancer. 2020 May 1;146(9):2599-2607
pubmed: 31490545
Mod Pathol. 1997 Mar;10(3):176-80
pubmed: 9071723
ISRN Surg. 2014 Jan 16;2014:841618
pubmed: 24527233
Anticancer Res. 2008 May-Jun;28(3B):1763-6
pubmed: 18630456
Cancer. 2005 Oct 25;105(5):253-62
pubmed: 15991244
Br J Cancer. 2012 Feb 28;106(5):975-81
pubmed: 22251922
Eur J Cancer. 2002 Nov;38(17):2229-42
pubmed: 12441259
Lancet Oncol. 2010 Mar;11(3):249-57
pubmed: 20089449
Arch Med Res. 2009 Aug;40(6):435-42
pubmed: 19853183
J Natl Cancer Inst. 2009 Jan 21;101(2):88-99
pubmed: 19141778
Am J Clin Pathol. 2011 Mar;135(3):468-75
pubmed: 21350104
Mod Pathol. 2008 Sep;21(9):1067-74
pubmed: 18552822
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Lancet. 2006 Feb 11;367(9509):489-98
pubmed: 16473126
J Natl Cancer Inst. 2002 Jan 16;94(2):102-7
pubmed: 11792748
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):351-4
pubmed: 19640171
Cancer Treat Rev. 2009 May;35(3):210-20
pubmed: 19261387
Obstet Gynecol. 2016 Oct;128(4):e111-e130
pubmed: 27661651
Am J Clin Pathol. 2012 Apr;137(4):516-42
pubmed: 22431528
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv
pubmed: 19891902